Skip to main content
SpringerLink
Log in

Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction

  • Research Articles
  • Drug Actions
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

The present study has been designed to investigate the effect of rosiglitazone, a peroxisome proliferator activated receptor γ agonist in sodium arsenite-induced vascular endothelial dysfunction (VED) in rats. The rats were administered sodium arsenite (1.5 mg/kg/day, i.p., 2 weeks) to induce VED. The development of VED was assessed by employing isolated aortic ring preparation and estimating serum nitrite/nitrate concentration. Further, the integrity of the aortic endothelium was assessed histologically using haematoxylin-eosin staining. Moreover, the oxidative stress was assessed by estimating serum thiobarbituric acid reactive substances, aortic reactive oxygen species and reduced form of glutathione. The administration of sodium arsenite produced VED by impairing acetylcholine-induced endothelium dependent relaxation, diminishing the integrity of vascular endothelium and decreasing the serum nitrite/nitrate concentration. In addition, sodium arsenite was noted to produce oxidative stress as it increased serum thiobarbituric acid reactive substances and aortic reactive oxygen species and consequently decreased glutathione. Treatment with rosiglitazone (3 mg/kg/day, p.o., 2 weeks and 5 mg/kg/day, p.o., 2 weeks) significantly prevented sodium arsenite-induced VED by enhancing acetylcholine-induced endothelium dependent relaxation, improving the integrity of vascular endothelium, increasing the nitrite/nitrate concentration and decreasing the oxidative stress. However, the vascular protective effect of rosiglitazone was markedly abolished by co-administration of nitric oxide synthase inhibitor, N-Omega-Nitro-L-Arginine Methyl Ester (L-NAME) (25 mg/kg/day, i.p., 2 weeks). Thus, it may be concluded that rosiglitazone reduces oxidative stress, activates eNOS and enhances the generation of nitric oxide to prevent sodium arsenite-induced VED in rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Albertini, J. P., McMorn, S. O., Chen, H., Mather, R. A., and Valensi, P., Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis, 195, E159–166 (2007).

    Article  CAS  PubMed  Google Scholar 

  • Balakumar, P., Kaur, T., and Singh, M., Potential targets to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology, 245, 49–64 (2008).

    Article  CAS  PubMed  Google Scholar 

  • Barchowsky, A., Klei, L. R., Dudek, E. J., Swartz, H. M., and James, P. E., Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med., 27, 1405–1412 (1999).

    Article  CAS  PubMed  Google Scholar 

  • Chen, C. J., Hsueh, Y. M., Lai, M. S., Shyu, M. P., Chen, S. Y., Wu, M. M., Kuo, T. L., and Tai, T. Y., Increased prevalence of hypertension and long-term arsenic exposure. Hypertension, 25, 53–60 (1995).

    PubMed  Google Scholar 

  • Chen, Y., Parvez, F., Gamble, M., Islam, T., Ahmed, A., Argos, M., Graziano, J. H., and Ahsan, H., Arsenic exposure at low-to-moderate levels and skin lesions, arsenic metabolism, neurological functions, and biomarkers for respiratory and cardiovascular diseases: review of recent findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. Toxicol. Appl. Pharmacol., 239, 184–192 (2009).

    Article  CAS  PubMed  Google Scholar 

  • Clayden, E. C., Practical section cutting and staining. Churchill Livingstone, London, pp. 115, (1971).

    Google Scholar 

  • Davignon, J. and Ganz, P., Role of endothelial dysfunction in atherosclerosis. Circulation, 109, 11127–11132 (2004).

    Google Scholar 

  • Desjardins, F. and Balligand, J. L., Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin. Belg., 61, 326–334 (2006).

    CAS  PubMed  Google Scholar 

  • Duvall, W. L., Endothelial dysfunction and antioxidants. Mt. Sinai J. Med., 72, 71–80 (2005).

    PubMed  Google Scholar 

  • Gingerich, S. and Krukoff, T. L., Estrogen modulates endothelial and neuronal nitric oxide synthase expression via an estrogen receptor beta-dependent mechanism in hypothalamic slice cultures. Endocrinology, 146, 2933–2941 (2005).

    Article  CAS  PubMed  Google Scholar 

  • Gonon, A. T., Bulhak, A., Labruto, F., Sjöquist, P. O., and Pernow J., Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res. Cardiol., 102, 80–89 (2007).

    Article  CAS  PubMed  Google Scholar 

  • Grossini, E., Molinari, C., Caimmi P. P., Uberti, F., and Vacca, G., Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel. Br. J. Pharmacol., 156, 250–261 (2009).

    Article  CAS  PubMed  Google Scholar 

  • Hansen, E. S., International commission for protection against environmental mutagens and carcinogens ICPEMC working paper 7/1/2. Shared risk factors for cancer and atherosclerosis-a review of the epidemiological evidence. Mutat. Res., 239, 163–179 (1990).

    CAS  PubMed  Google Scholar 

  • Hwang, J., Kleinhenz, D. J., Rupnow, H. L., Campbell, A. G., Thulé, P. M., Sutliff, R. L., and Hart, C. M., The PPAR gamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul. Pharmacol., 46, 456–462 (2007).

    Article  CAS  PubMed  Google Scholar 

  • Izquierdo-Vega, J. A., Soto, C. A., Sanchez-Peña, L. C., and Del Razo, L. M., Diabetogenic effects and pancreatic oxidative damage in rats subchronically exposed to arsenite. Toxicol. Lett., 160, 135–142 (2006).

    Article  CAS  PubMed  Google Scholar 

  • Jermendy, G., PPARγ agonists-Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes. Diabetes. Res. Clin. Pract., 78, S29–39 (2007).

    Article  CAS  Google Scholar 

  • Jindal, S., Singh, M., and Balakumar, P., Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int. J. Cardiol., 128, 283–291 (2008).

    Article  Google Scholar 

  • Jollow, D., Mitchell, L., Zampaglione, N., and Gillete, J., Bromobenze induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzenoxide as the hepatotoxic intermediate. Pharmacol., 11, 151–169 (1974).

    Article  CAS  Google Scholar 

  • Kashyap, V. S., Reil, T. D., Moore, W. S., Hoang, T. X., Gelabert, H. A., Byrns. R. E., Ignarro. L. J., and Freischlag. J. A., Acute arterial thrombosis causes endothelial dysfunction: a new paradigm for thrombolytic therapy. J. Vasc. Surg., 34, 323–329 (2001).

    Article  CAS  PubMed  Google Scholar 

  • Kawashima, S. and Yokoyama, M., Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 24, 998–1005 (2004).

    Article  CAS  PubMed  Google Scholar 

  • Kinoshita, H., Azma, T., Iranami, H., Nakahata, K., Kimoto, Y., Dojo, M., Yuge, O., and Hatano, Y., Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose. J. Pharmacol. Exp. Ther., 318, 312–318 (2006).

    Article  CAS  PubMed  Google Scholar 

  • Lee, P. C., Ho, I. C., and Lee, T. C., Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol. Sci., 85, 541–550 (2005).

    Article  CAS  PubMed  Google Scholar 

  • Ma, F. X., Liu, L. Y., and Xiong, X. M., Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol. Sin., 24, 1027–1032 (2003).

    CAS  PubMed  Google Scholar 

  • Maytin, M., Leopold, J., and Loscalzo, J., Oxidant stress in the vasculature. Curr. Atheroscler. Rep., 1, 156–164 (1999).

    Article  CAS  PubMed  Google Scholar 

  • Mittra, S. and Singh, M., Possible mechanism of captopril induced endothelium-dependent relaxation in isolated rabbit aorta. Mol. Cell. Biochem., 183, 63–67 (1998).

    Article  CAS  PubMed  Google Scholar 

  • Panunti, B. and Fonseca, V., Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul. Pharmacol., 45, 29–35 (2006).

    Article  CAS  PubMed  Google Scholar 

  • Papaharalambus, C. A. and Griendling, K. K., Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc. Med., 17, 48–54 (2007).

    Article  CAS  PubMed  Google Scholar 

  • Pesic, S., Radenkovic, M., and Grbovic, L., Endothelial dysfunction: mechanisms of development and therapeutic options. Med. Pregl., 59, 335–341 (2006).

    Article  PubMed  Google Scholar 

  • Pieper, G. M., Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J. Cardiovasc. Pharmacol., 29, 8–15 (1997).

    Article  PubMed  Google Scholar 

  • Potenza, M. A., Gagliardi, S., De Benedictis, L., Zigrino, A., Tiravanti, E., Colantuono, G., Federici, A., Lorusso, L., Benagiano, V., Quon, M. J., and Montagnani, M., Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am. J. Physiol. Endocrinol. Metab., 297, E685–694 (2009).

    Article  CAS  PubMed  Google Scholar 

  • Puddu, P., Puddu, G.M., and Muscari, A., Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? Int. J. Cardiol., 90, 133–140 (2003).

    Article  PubMed  Google Scholar 

  • Ríos-Vázquez, R., Marzoa-Rivas, R., Gil-Ortega, I., and Kaski, J. C., Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am. J. Cardiovasc. Drugs, 6, 231–242 (2006).

    Article  PubMed  Google Scholar 

  • Rush, J. W., Denniss, S. G., and Graham, D. A., Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can. J. Appl. Physiol., 30, 442–474 (2005).

    CAS  PubMed  Google Scholar 

  • Sastry, K. V., Moudgal, R. P., Mohan, J., Tyagi, J. S., and Rao, G. S., Spectrophotometric of serum nitrite and nitrate by copper-cadmium alloy. Anal. Biochem., 306, 79–82 (2002).

    Article  CAS  PubMed  Google Scholar 

  • Satoh, H., Tsukamoto, K., Hashimoto, Y., Hashimoto, N., Togo, M., Hara, M., Maekawa, H., Isoo, N., Kimura, S., and Watanabe, T., Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR gamma on vascular endothelial function. Biochem. Biophys. Res. Commun., 254, 757–763 (1999).

    Article  CAS  PubMed  Google Scholar 

  • Savoia, C. and Schiffrin, E. L., Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin. Sci. (Lond)., 112, 375–384 (2007).

    Article  CAS  Google Scholar 

  • Shah, D. I. and Singh, M., Possible role of Akt to improve vascular endothelial dysfunction in diabetic and hyperhomocysteinemic rats. Mol. Cell. Biochem., 295, 65–74 (2007).

    Article  CAS  PubMed  Google Scholar 

  • Smith, K. R., Klei, L. R., and Barchowsky, A., Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol., 280, L442–449 (2001).

    CAS  PubMed  Google Scholar 

  • Touyz, R. M. and Schiffrin, E. L., Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol., 45, 19–28 (2006).

    Article  CAS  PubMed  Google Scholar 

  • Tsou, T. C., Tsai, F. Y., Hsieh, Y. W., Li, L. A., Yeh, S. C., and Chang, L. W., Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol. Appl. Pharmacol., 208, 277–284 (2005).

    Article  CAS  PubMed  Google Scholar 

  • Vanhoutte, P. M., Aging and endothelial dysfunction. Euro. Heart J., 4, A8–17 (2004).

    Google Scholar 

  • Verma, S. and Szmitko, P. E., The vascular biology of peroxisome proliferators activated receptors: Modulation of atherosclerosis. Can. J. Cardiol., 22, B12–17 (2006).

    Google Scholar 

  • Wang, H. D., Pagano, P. J., Du, Y., Cayatte, A. J., Quinn, M. T., Brecher, P., and Cohen, R. A., Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ. Res., 82, 810–818 (1998).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, 147002, India

    Tajpreet Kaur & Rajesh Kumar Goel

  2. Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga, 142001, India

    Pitchai Balakumar

  3. Pharmacology Division, Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, 147002, India

    Rajesh Kumar Goel

Authors
  1. Tajpreet Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajesh Kumar Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pitchai Balakumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajesh Kumar Goel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaur, T., Goel, R.K. & Balakumar, P. Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Arch. Pharm. Res. 33, 611–618 (2010). https://doi.org/10.1007/s12272-010-0416-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-010-0416-x

Key words

Search

Navigation